scholarly journals The Hydrogen Sulfide-Vitamin B12-Folic Acid Axis: An Intriguing Issue in Chronic Kidney Disease. A Comment on Toohey JI: “Possible Involvement of Hydrosulfide in B12-Dependent Methyl Group Transfer”. Molecules 2017, 22, 582, pii: E582

Molecules ◽  
2017 ◽  
Vol 22 (7) ◽  
pp. 1216 ◽  
Author(s):  
Giuseppe Cianciolo ◽  
Maria Cappuccilli ◽  
Keyword(s):  
Chronic Kidney Disease ◽  
Hydrogen Sulfide ◽  
Folic Acid ◽  
Kidney Disease ◽  
Vitamin B12 ◽  
Methyl Group ◽  
Group Transfer ◽  
Methyl Group Transfer

scholarly journals Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease

2019 ◽  
Vol 44 (5) ◽  
pp. 1158-1165 ◽  
Author(s):  
Jiu-Hong Li ◽  
Jun-Feng Luo ◽  
Ying Jiang ◽  
Yong-Jian Ma ◽  
Yong-Qiang Ji ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Folic Acid ◽  
Kidney Disease ◽  
Blood Cell ◽  
Vitamin B12 ◽  
Red Blood Cell ◽  
Early Stage ◽  
Renal Anemia ◽  
Ckd Stage ◽  
Stage 1

Background: Although reduced red blood cell (RBC) lifespan has been reported to be a contributory factor to anemia in patients with end-stage chronic kidney disease (CKD), there are limited data regarding RBC lifespan in early-stage CKD. Serum erythropoietin (EPO) is considered a primary causative factor of renal anemia. The aims of this study were to compare the RBC lifespan, serum EPO levels, and other renal anemia indicators across CKD-stage groups of patients and to analyze the impacts of etiological factors on renal anemia. Methods: A cohort of 74 non-smoking patients with CKD were enrolled, including 15 in stage 1, 18 in stage 2, 15 in stage 3, 15 in stage 4, and 11 in stage 5. RBC lifespan was determined by CO breath tests. Potential correlations of hemoglobin (Hb) concentration with RBC lifespan, reticulocyte count (Ret), and levels of EPO, ferritin, folic acid, and vitamin B12 were analyzed. Results: CKD progression was associated with decreases in (Hb) and RBC lifespan. RBC lifespan durations in CKD stages 1–5 were 122 ± 50, 112 ± 26, 90 ± 32, 88 ± 28, and 60 ± 24 days, respectively. RBC lifespan means for the stage 3, 4 and 5 groups were significantly shorter than those for the stage 1 and 2 groups. Serum EPO did not differ significantly between the CKD stage groups. (Hb) correlated directly with RBC lifespan (r = 0.372, p = 0.002) and Ret (r = 0.308, p = 0.011), but did not correlate with serum EPO, ferritin, folic acid, or vitamin B12 levels. Conclusions: Reduced RBC lifespan in early-stage CKD, demonstrated in this study, suggests that increased RBC destruction may play a more important etiological role in renal anemia than other indicators in patients with CKD.

scholarly journals Study of vitamin B12 deficiency in chronic kidney disease

2020 ◽  
Vol 7 (2) ◽  
pp. 303
Author(s):  
Vinod Ananda Dandge ◽  
Dhruv Variya
Keyword(s):  
Chronic Kidney Disease ◽  
Folic Acid ◽  
Kidney Disease ◽  
Vitamin B12 ◽  
Serum Vitamin ◽  
Vitamin B12 Deficiency ◽  
Left Ventricular ◽  
Nutritional Deficiencies ◽  
Folic Acid Deficiency ◽  
B12 Deficiency

Background: Chronic Kidney Disease (CKD) is a growing health burden and important cause of morality and morbidity worldwide as well as India. Anaemia a feature of CKD, is multifactorial, one of the most important factor responsible for the development of left ventricular hypertrophy, diastolic and later systolic dysfunction and cardiovascular disease, which is the single most important contributor to the mortality in CKD. Severe Chronic Kidney Disease has an adverse effect on haematopoiesisis. Lack of erythropoietin, Iron deficiency anaemia and shortened red cell life span, Nutritional deficiency or deranged metabolism of vitamins is the major factors contributing to anaemia in CRF. Patients with CKD show megaloblastosis on examination of the bone marrow. Suggestive of Vitamin B12 and folic acid deficiency might Be Additional Factors Contributing to inadequate Haematopoiesis in uremia. Patients with CKD are at higher risk for nutritional deficiencies due to medication interactions, dietary restrictions and malnutrition. The dialysis procedure itself may cause loss of vitamin B12, Folic acid and there deficiency.Methods: Sample size of 80 cases of CKD patients aged between 18-80 year admitted in SMIMER Hospital were included in study. Serum vitamin B12 Level was checked, correlation B12 deficiency with duration of CKD was observed.Results: It was observed that, 47 cases of CKD had vitamin B12 deficiency. The mean duration of CKD is more in B12deficient group as compared to Normal Group and also finds the higher proportion of vitamin B12 deficiency in CKD patients.Conclusions: Serum vitamin B12 level testing should be recommended routinely in patients with CKD and All the treating Nephrologists should anticipate the deficiency of vitamin B12 in CKD patients.

scholarly journals Novel insights into the m6A-RNA methyltransferase METTL3 in cancer

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Yiqing Cai ◽  
Rui Feng ◽  
Tiange Lu ◽  
Xiaomin Chen ◽  
Xiangxiang Zhou ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Human Cancer ◽  
Rna Modification ◽  
Rapid Progression ◽  
Antitumor Therapy ◽  
Promoting Effect ◽  
Methyl Group ◽  
Group Transfer ◽  
Functional Regulation ◽  
Methyl Group Transfer

AbstractN6-methyladenosine (m6A) is a prevalent internal RNA modification in higher eukaryotic cells. As the pivotal m6A regulator, RNA methyltransferase-like 3 (METTL3) is responsible for methyl group transfer in the progression of m6A modification. This epigenetic regulation contributes to the structure and functional regulation of RNA and further promotes tumorigenesis and tumor progression. Accumulating evidence has illustrated the pivotal roles of METTL3 in a variety of human cancers. Here, we systemically summarize the interaction between METTL3 and RNAs, and illustrate the multiple functions of METTL3 in human cancer. METLL3 is aberrantly expressed in a variety of tumors. Elevation of METTL3 is usually associated with rapid progression and poor prognosis of tumors. On the other hand, METTL3 may also function as a tumor suppressor in several cancers. Based on the tumor-promoting effect of METTL3, the possibility of applying METTL3 inhibitors is further discussed, which is expected to provide novel insights into antitumor therapy.

Methyl group transfer upon gas phase decomposition of protonated methyl benzoate and similar compounds

2018 ◽  
Vol 53 (5) ◽  
pp. 379-384 ◽  
Author(s):  
Rafał Frański ◽  
Błażej Gierczyk ◽  
Maciej Zalas ◽  
Wojciech Jankowski ◽  
Marcin Hoffmann
Keyword(s):  
Gas Phase ◽  
Methyl Benzoate ◽  
Phase Decomposition ◽  
Methyl Group ◽  
Group Transfer ◽  
Methyl Group Transfer

Homocystein and folic acid in chronic kidney disease: clinical and predictive significance

Nephrology ◽  
2021 ◽  
Vol 3_2021 ◽  
pp. 49-56
Author(s):  
I.T. Murkamilov Murkamilov ◽  
K.A. Aitbaev Aitbaev ◽  
V.V. Fomin Fomin ◽  
Zh.A. Murkamilova Murkamilova ◽  
F.A. Yusupov Yusupov ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Folic Acid ◽  
Kidney Disease

scholarly journals Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease

Nutrients ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 2192
Author(s):  
Hsun Yang ◽  
Shiun-Yang Juang ◽  
Kuan-Fu Liao ◽  
Yi-Hsin Chen
Keyword(s):  
Chronic Kidney Disease ◽  
Folic Acid ◽  
Kidney Disease ◽  
Index Date ◽  
Dialysis Initiation ◽  
Nutrient Loss ◽  
Research Database ◽  
Advanced Chronic Kidney Disease ◽  
Stage Renal Disease ◽  
End Stage

Background: We hypothesized that the nutrient loss and chronic inflammation status may stimulate progression in advanced chronic kidney disease. Therefore, we aimed to generate a study to state the influence of combined nutritional and anti-inflammatory interventions. Methods: The registry from the National Health Insurance Research Database in Taiwan was searched for 20–90 years individuals who had certified end-stage renal disease. From January 2005 through December 2010, the diagnosis code ICD-9 585 (chronic kidney disease, CKD) plus erythropoiesis-stimulating agent (ESA) use was defined as entering advanced chronic kidney disease. The ESA starting date was defined as the first index date, whereas the initiation day of maintenance dialysis was defined as the second index date. The duration between the index dates was analyzed in different medical treatments. Results: There were 10,954 patients analyzed. The combination therapy resulted in the longest duration (n = 2184, median 145 days, p < 0.001) before the dialysis initiation compared with folic acid (n = 5073, median 111 days), pentoxifylline (n = 1119, median 102 days, p = 0.654), and no drug group (control, n = 2578, median 89 days, p < 0.001). Lacking eGFR data and the retrospective nature are important limitations. Conclusions: In patients with advanced CKD on the ESA treatment, the combination of folic acid and pentoxifylline was associated with delayed initiation of hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document